A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media

Objectives:Several recent publications have suggested an association between the administration of gadolinium (Gd)-based contrast agents and the occurrence of Nephrogenic Systemic Fibrosis (NSF), an acquired disorder marked by skin thickening and fibrosis occurring in patients with severe renal dysfunction. The aim of this study was to establish a preclinical experimental setting to investigate the possible link between NSF and Gd-based contrast agents, and specifically the role of Gd and/or depletion of endogenous metal ions as possible triggers for NSF. Materials and Methods:Thirty-five healthy male rats received repeated intravenous injections of Magnevist (gadopentetate dimeglumine; Gd-DTPA), Omniscan (gadodiamide; Gd-DTPA-BMA), or gadodiamide without caldiamide at a dose of 2.5 mmol Gd/kg body weight over at least 20 days to simulate the exposure to Gd-containing contrast agents in patients with severe renal dysfunction. In addition, caldiamide (the excess ligand in Omniscan) and Gd-ethylenediamine tetraacetic acid (Gd-EDTA) as a positive control, and saline as a negative control were studied. Histopathologic and immunohistochemical analysis of the skin was performed. Gd and zinc concentrations were measured in skin, femur, and liver tissue by atomic emission spectrometry. Results:Rats receiving Gd-EDTA, gadodiamide without caldiamide, and Omniscan developed epidermal ulceration and acanthosis, dermo-epidermal clefts, minimal-to-slight dermal fibrosis, and increased dermal infiltration of different cells, partly positive for CD34 fibrocytes. No such NSF-like macroscopic lesions were observed in the saline, caldiamide, and Magnevist groups. High Gd concentrations in the skin were found in the Gd-EDTA, gadodiamide without caldiamide, and Omniscan groups. In the Magnevist group, Gd levels in the skin were 10-times lower than in the Omniscan-treated animals but elevated compared with saline. Conclusions:A preclinical experimental setting has been established where NSF-like lesions could be observed. The link between the application of Gd-based contrast media and the induction of NSF-like lesions was established. The data indicate that the observed skin lesions are related to the release of Gd and not to the depletion of endogenous ions. The investigations further suggest potential importance of the stability of Gd-based contrast agents.

[1]  Raimund Erbel,et al.  Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. , 2009, Journal of the American College of Cardiology.

[2]  B. Watschinger,et al.  Sympathische Überaktivität und Niere , 2003, Wiener Klinische Wochenschrift.

[3]  W. Haschek,et al.  Skin and Oral Mucosa , 2009 .

[4]  G. Saab,et al.  Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis? , 2007, Radiology.

[5]  M. Tweedle "Stability" of gadolinium chelates. , 2007, The British journal of radiology.

[6]  H. Schmitt-Willich Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.

[7]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[8]  E. Kanal,et al.  Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. , 2007, Radiology.

[9]  V. Runge,et al.  Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.

[10]  P. Champéroux,et al.  Cardiovascular Safety of Gadoterate Meglumine (Gd-DOTA) , 2007, Investigative radiology.

[11]  Gerhard Adam,et al.  Clinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA) , 2007, Investigative radiology.

[12]  S. Jimenez,et al.  Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: clinical aspects. , 2007, Skinmed.

[13]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[14]  J. Finsterer,et al.  Dermal and extra-dermal manifestations of gadolinium-triggered nephrogenic fibrosing dermopathy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Kevan G. Lewis,et al.  Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum‐like changes , 2006, Journal of cutaneous pathology.

[16]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[17]  M. Knopp,et al.  Assessment of Utilization and Pharmacovigilance Based on Spontaneous Adverse Event Reporting of Gadopentetate Dimeglumine as a Magnetic Resonance Contrast Agent After 45 Million Administrations and 15 Years of Clinical Use , 2006, Investigative radiology.

[18]  S. Cowper,et al.  Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients , 2006, Seminars in dialysis.

[19]  T. Grobner Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  T. Ishiguchi,et al.  Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. , 2005, Radiation medicine.

[21]  R. Elenitsas,et al.  Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.

[22]  J. Yamate,et al.  Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. , 2005, Journal of comparative pathology.

[23]  Susanne A. Fischer,et al.  In Vitro Cultivation of an Insect Microsporidian Tubulinosema ratisbonensis in Mammalian Cells , 2005, The Journal of eukaryotic microbiology.

[24]  S. Jimenez,et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.

[25]  D. Lipsker,et al.  Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis , 2004, The British journal of dermatology.

[26]  Shawn Cowper,et al.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood. , 2004, The international journal of biochemistry & cell biology.

[27]  J. English,et al.  Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy , 2004, Journal of cutaneous pathology.

[28]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[29]  S. Cowper Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.

[30]  W. Shoji,et al.  Reduction of recipient macrophages by gadolinium chloride prevents development of obliterative airway disease in a rat model of heterotopic tracheal transplantation , 2003, Transplantation.

[31]  A. Habicht,et al.  [Sympathetic overactivity and the kidney]. , 2003, Wiener klinische Wochenschrift.

[32]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. , 2003, The American Journal of dermatopathology.

[33]  P. Leboit,et al.  Nephrogenic Fibrosing Dermopathy , 2001, The American Journal of dermatopathology.

[34]  E.,et al.  Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging : Theory and Design , 2001 .

[35]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[36]  E. Brücher,et al.  The rates of the exchange reactions between [Gd(DTPA)]2- and the endogenous ions Cu2+ and Zn2+: a kinetic model for the prediction of the in vivo stability of [Gd(DTPA)]2-, used as a contrast agent in magnetic resonance imaging. , 2000, Chemistry.

[37]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[38]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[39]  A. Reid,et al.  Gadolinium Chloride Toxicity in the Rat , 1997, Toxicologic pathology.

[40]  W. Gibby,et al.  Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.

[41]  W. Gibby,et al.  Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. , 1996, Investigative radiology.

[42]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[43]  H. Weinmann,et al.  Pharmacokinetics, Dose Proportionality, and Tolerability of Gadobutrol after Single Intravenous Injection in Healthy Volunteers , 1994, Investigative radiology.

[44]  E. Holtz,et al.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.

[45]  P. Wedeking,et al.  Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. , 1992, Magnetic resonance imaging.

[46]  G. Krestin,et al.  Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. , 1991, Investigative radiology.

[47]  S. Quay,et al.  A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.

[48]  J. Hagan,et al.  Reaction of gadolinium chelates with endogenously available ions. , 1991, Magnetic resonance imaging.

[49]  W. Cacheris,et al.  The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.

[50]  G. Krinke,et al.  Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B6 in Rat Primary Sensory Neurons , 1985, Journal of neuropathology and experimental neurology.

[51]  R. Brasch,et al.  Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. , 1984, AJR. American journal of roentgenology.

[52]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.